The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices have updated guidance regarding the use of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine.
Results from an analysis presented at the 2019 ASH Annual Meeting reveal significant risk factors for worse treatment response after CD-19 chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
Findings from a retrospective study being presented at the 2019 ASH Annual Meeting support the use of bevacizumab to treat chronic bleeding and anemia in patients with hereditary hemorrhagic telangiectasia (HHT).
The addition of aspirin to direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) or nonvalvular atrial fibrillation (NVAF) resulted in more bleeding events without significant improvement in the incidence of thrombosis, according to a study presented at the 2019 ASH…
Back to Top
Stay in the know. Population Health Learning Network Newsletter